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doi:10.1016/j.ejvs.2009.11.013Abstract Objectives/design: In symptomatic patients treated with ipsilateral carotid artery
stenting (CAS) plus intensive lipid lowering, we assessed the changes of osteopontin (OPN), os-
teoprotegerin (OPG) and the Gray-Scale Median (GSM) score contralateral to symptomatic
carotid stenosis.
Materials/methods: Forty-six symptomatic patients (group A) with significant carotid stenosis
(North American Symptomatic Carotid Endarterectomy Trial (NASCET): >70%) underwent ipsi-
lateral CAS. Those patients had simultaneously contralateral low-grade carotid stenosis (NAS-
CET: 30e69%). Group B included 67 symptomatic patients with low-grade bilateral carotid
stenosis (NASCET: 30e69%), but without indications for revascularisation. All patients were
treated with atorvastatin (10e80 mg) to target low-density lipoprotein (LDL)< 100 mg dl1.
Blood samples and plaques’ GSM score contralateral to brain infarct were assayed at baseline
and after 6 months.
Results: At baseline, there were no significant differences between groups (p> 0.05). Six-
month atorvastatin treatment equivalently improved lipid profile in both groups (p< 0.05).
The parameters hsCRP, OPN and OPG were significantly down-regulated within both groups,ting 3e6 September 2009, European Society for Vascular Surgery, Oslo, Norway.
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CAS Plus Statin Increases Contralateral GSM 259but to a greater extent in group A (p< 0.05). Besides this, contralateral GSM score was signif-
icantly improved from baseline in both groups (p < 0.01), but that increment was more
pronounced in group A (vs. group B; pZ 0.041). These changes were inversely correlated with
changes in OPN (pZ 0.014), OPG (pZ 0.011) and LDL (pZ 0.041).
Conclusion: Ipsilateral CAS plus intensive lipid-lowering therapy was associated with enhanced
contralateral carotid plaque stability and attenuated inflammatory burden and calcification
inhibitors to a greater extent than atorvastatin therapy alone in patients with bilateral carotid
stenosis.
ª 2009 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.Carotid plaque echolucency is a well-established index of
plaque vulnerability, and has been found to reliably predict
plaque composition and the occurrence of cerebrovascular
ischaemic events.1 Echolucent plaques are histologically
rich in lipid and macrophage and consist of less fibrous
tissue and less calcification, which make them vulnerable
and prone to rupture.2 The ultrasound-derived Gray-Scale
Median (GSM) score has emerged as a valid, quantified
index of carotid plaque echogenicity inversely associated
with plaque vulnerability.3
The combination of ultrasound indices with cardiovas-
cular biomarkers seems to be a noteworthy model for
effective cardiovascular risk stratification and monitoring of
therapeutic interventions. Among numerous cardiovascular
biomarkers, osteopontin (OPN) and osteoprotegerin (OPG)
constitute physiologically potent inhibitors of osteoclasto-
genesis and vascular calcification.4 Both of these pro-
inflammatory cytokines are highly expressed at macro-
phages- and foam cell-rich sites within the atherosclerotic
plaques.5 Accumulating evidence supports the association of
serum OPN and OPG with cardiovascular diseases6 and
carotid plaque vulnerability.3 Although pharmaceutical
modulation of vascular calcification inhibitors and carotid
echogenicity seems quite promising,7 data regarding their
long-term response to interventional procedure are missing.
The compounds 3-hydroxy-3-methylglutaryl coenzyme A
(HMG-CoA) reductase inhibitors (statins) administration is
the most commonly effective therapeutical intervention to
mitigate atherosclerosis.8 Numerous studies have demon-
strated resounding and sustained benefits from statins in
primary and secondary cardiovascular disease prevention.9
Besides lipid lowering, statins exerts ‘pleiotropic’ proper-
ties, including anti-inflammatory, anti-thrombogenic, anti-
oxidative and direct anti-atherogenic effects, leading to
atherosclerotic plaque stabilisation.8,9 Using GSM score, we
have recently shown the favourable effects of statin
therapy on carotid lesions echogenicity associated with
considerable suppression of OPN and OPG levels.7
Carotid artery stenting (CAS) has emerged as an alter-
native treatment for carotid artery disease, at least in
patients considered to be at increased risk for carotid
endarterectomy (CEA).10 The peri-procedural as well as the
long-term efficacy of CAS compared with CEA is the subject
of controversy, and more data are required.10 Perhaps,
a critical issue for improving CAS outcome could be the
concomitant medications. Nowadays, statin treatment is
advocated as an adjunct in CEA, minimising the peri- and
postoperative mortality and morbidity.11 This raises the
question of whether a similar benefit would translate into
outcomes of CAS. No prospective studies exist and it is stillquestionable whether unilateral carotid revascularisation
could beneficially influence either serum cardiovascular
biomarkers or the natural history of the contralateral
carotid plaques.
Thus, the aim of the present study was to evaluate the
changes of serum vascular calcification inhibitors and GSM
score of the contralateral atherosclerotic lesions after
ipsilateral CAS plus atorvastatin treatment in patients with
bilateral carotid stenosis.
Materials and Methods
Patients and study design
This was a two-centre, prospective, open-label trial.
Initially, 466 consecutive patients were admitted, between
January 2005 and December 2007, to our hospitals with
recent, within 15 days, ischaemic stroke or transient
ischaemic attack (TIA) attributed to carotid atheroscle-
rosis. Among them, we selected 132 patients with stenosis
of both internal carotid arteries (ICAs) (North American
Symptomatic Carotid Endarterectomy Trial (NASCET) range:
30e99%). The degree of carotid stenosis was initially
measured using B-mode and Doppler ultrasound, as
described in the following section. In cases of borderline
ultrasound, calculated degree of carotid stenosis (NASCET:
70 10%), patients underwent digital subtraction angiog-
raphy (DSA) to further validate the grade of carotid
stenosis.12 We excluded patients with: indications for
intervention of both ICAs due to significant symptomatic or
asymptomatic stenosis, autoimmune or life-threatening
diseases, recently diagnosed/untreated hypothyroidism,
osteoporosis, coronary artery disease or overt cardiac-
origin symptoms, atrial fibrillation, liver (ALT> 2.5 times
higher than the upper normal limit) or renal (creatinine
levels> 2.0 mg dl1) impairment, ongoing use of lipid-
lowering medications and contraindications to the use of
statins or CAS. We finally enrolled 117 patients (47 men and
70 women) who were divided into two groups:
 Group A (NZ 48): Patients with recent stroke or TIA,
ascribed to significant ipsilateral carotid stenosis (NAS-
CET: >70%), underwent CAS of the culprit lesion. Those
patients had simultaneously contralateral carotid
stenosis without indications for revascularisation (NAS-
CET: 30e69%). In addition to ultrasound examination, all
patients of this group underwent pre-procedural DSA.
The interventional procedures were performed under
local anaesthesia, systemic heparinisation and cerebral
260 N.P.E. Kadoglou et al.deviceprotection. ‘Technical success’wasdefinedas the
ability of treating the stenosis with less than 30% residual
stenosis. Neurological outcome was evaluated both at
the end of the procedure and in the following 24 h by
a neurologist according to the National Institutes of
Health Stroke Scale (NIHSS) and the modified Rankin
Scale (mRS). Among CAS and CEA, we selected CAS
performance as a routine procedure in our high-volume
centres owing to the very low rates of peri- and post-
procedural adverse events.10
 Group B (NZ 69): Patients with recent stroke or TIA
attributed to ipsilateral carotid atherosclerosis and
bilateral carotid stenosis, but without indications for
revascularisation (NASCET: 30e69%).
The diagnosis of stroke/TIA and its relationship with
ipsilateral carotid lesions was based on the comparative
evaluation of medical history, neurological examination,
brain computed tomography (CT) or magnetic resonance
imaging (MRI), when CT findings were questionable.
Patients of both groups were treated with atorvastatin for 6
months. Atorvastatin treatment initiated at the time of
diagnosis and its dose was gradually titrated (10d80 mg) to
target LDL< 100 mg dl1, at 6 weeks’ intervals. Patients’
compliance was closely monitoring by calculating the
number of statin pills, already taken, every 2 months. It
was considered effective if at least 90% of estimated study
medication had been received. In addition, dual anti-
platelet therapy (aspirin 100 mg plus clopidogrel 75 mg)
started 3 days before the stenting procedure and continued
for the whole duration of the study in group A, while group
B received aspirin 100 mg or clopidogrel 75 mg throughout
the study. The concomitant anti-hypertensive and hypo-
glycaemic medications remained unaltered, unless it was
deemed medically necessary. At baseline, patients were
given written dietary and exercise recommendations and
smokers were encouraged to cease smoking.
Blood sampling, ultrasound of both carotids and
anthropometrical parameters assessment, such as body
mass index (BMI), waist-to-hip ratio (WHR) and blood
pressure (BP), were performed at baseline and at the end of
the study.13 We estimated the mean value of two consec-
utive measurements of BP with a 5-min interval. All
participants had been kept in a sitting position for 15 min
before BP measurement.
This study was approved by the Committee on Research
Ethics at our hospitals, in compliance with the ethical
guidelines of the Declaration of Helsinki. All participants
gave written informed consent prior to study entry.
Calculation of GSM Score and the Degree of Carotid
Stenosis
A carotid ultrasound examination was performed using a 7.5-
MHz probe of an ultrasound scanner (General Electric
Logiq700, Riverside, CA, USA). Only one operator, blinded to
patients’ clinical characteristics, performed all of the
carotid scans at the beginning and at the end of the study. .
The procedure of carotid ultrasound examination and image
analysis for GSM calculation has been previously described.7
Then, we calculated the GSM score of each carotid plaquecontralateral to the brain infarct and the average value was
considered for statistical analysis.
Basedonpeak systolic velocity (PSV) and ICA/CCAPSVratio
thresholds,14 ICA stenosis was initially categorised to the
following groups: <50%, 50e69%, >70%, near occlusion and
total occlusion. Then, we calculated the highest degree of
carotid stenosis in eachpatient using B-mode imaging. For this
purpose, we compared the diameter of the minimal residual
lumen (at the point of tightest ICA stenosis) and the diameter
of the normal ICA lumen distal to the bulb on longitudinal and
transverse images using colour-flow imaging.15 This is a well-
validated procedure in our laboratory and the results match
Doppler ultrasound findings. To get comparable images during
the second ultrasound examination, the stored baseline
images of each patient were simultaneously showed to the
operator on a computer screen.
Blood Parameters
Blood samples were collected after an overnight fast at the
beginning (preoperatively in group A) and at the end of the
study. Lipid parameters and fasting plasma glucose (FPG)
were immediately determined using standard enzymatic
methods (Olympus AU560, Hamburg, Germany). The rest of
blood samples were centrifuged at 5000 g for 7 min, and
serum was stored at80 C, until analysis in the same assay.
Measurements of HbA1c were made by high-performance
liquid chromatography (Menarini Diagnostics, Florence,
Italy).WeusedQuantikine enzyme-immunoassay (EIA) kits to
assay serum OPN (R&D Systems Inc., Minneapolis, MN, USA)
and OPG (Metra, San Diego, CA, USA) levels. The intra- and
inter-assay coefficients of variance (CVs) were 2.6% and 5.7%
for OPN and 7% and 6.8% for OPG, respectively. High-sensi-
tivity C-reactive protein (hsCRP) was measured by a nephe-
lometric assay (Dade Behrin, BNII, Marburg, Germany).
Statistical Analysis
Data are expressed as mean and  standard deviation (SD).
Normality of distributionwas assessed by KolmogoroveSmirnov
test. Comparisons of parametric parameters within and
betweengroupswereanalysedbypaired samplesandStudent’s
t-test, respectively. Chi-square test was used for categorical
data. To test correlations between the changes of OPN, OPG
and GSM throughout the study, Pearson’s correlation was used.
Standard multiple regression analysis assessed the dependent
association of changes in GSM with the changes of the rest of
significant parameters. All analyses were carried out by SPSS
13.0 software package (SPSS Inc., Chicago, IL, USA). Two-tailed
p< 0.05 was considered as statistically significant.
Results
Patients’ characteristics at baseline
Baseline clinical characteristics of the groups are shown in
Tables 1 and 2. In general, four patients had major
complications and discontinued the study. Two patients in
group A developed reversible stroke early after interven-
tion, while in group B, one patient underwent coronary
angioplasty due to angina pectoris and one patient
Table 1 Baseline characteristics of the patients.
Group A Group B p-Value
Number 46 67 -
Male/Female 16/30 29/39 NS
Active smoking, n 17 (36.96%) 20 (29.41%) NS
Diabetes mellitus, n 17 (36.96%) 21 (30.88%) NS
Hypertension, n 35 (76.09%) 46 (67.65%) NS
Age (y) 66.76 7.31 64.91 10.36 0.437
Diabetes duration (y)a 5.75 4.1 7.34 4.31 0.318
hsCRP (mg/L) 6.61 2.69 5.91 2 0.391
Osteopontin (ng/ml) 84.74 41.91 79.3 25.88 0.507
Osteoprotegerin (pmol/L) 8.86 3.47 9.05 2.65 0.687
GSM score 74.1 28.26 70.47 27.83 0.739
Data are mean SD. Group A, CASþ atorvastatin therapy; Group B, atorvastatin therapy; n, number of patients; y, years; NS, non-
significant.
a Comparison between groups for diabetes duration was performed only in the diabetic subgroups.
CAS Plus Statin Increases Contralateral GSM 261experienced stroke. Thereby, 46 and 67 patients in groups A
and B, respectively, completed the entire study and their
data were analysed. Among smokers, only seven patients in
group A and three patients in group B ceased smoking
throughout the study despite our intensive encouragement.
The large number of statin-free patients with carotid
stenosis entering our study could be attributed to their low
compliance with their physicians’ recommendations,
despite the high incidence of concomitant diabetes or
hypertension. Unfortunately, the usage of statins in primary
and secondary cardiovascular disease prevention is not
widely accepted by patients without overt cardiovascular
diseases. In general, patients without overt clinical
cardiovascular symptoms or with unknown carotid stenosis
are predominantly under-treated. No adverse event related
to atorvastatin usage was recorded throughout the study,
while satisfactory ultrasound images, proper for computer
analysis, were obtained in all participants.Table 2 Time course of clinical and biochemical parameters dur
in both groups.
Group A (NZ 46)
Baseline 6 months
BMI (kg/m2) 29.58 3 28.92 4.1
WHR 0.95 0.08 0.94 0.09
SBP (mmHg) 132.7 13.47 128.68 17.47
DBP (mmHg) 77.03 7.31 73.42 10
HbA1c (%)a 6.48 1.48 5.97 0.51*
FPG (mg/dl) 135.8 46 110.4 31.8
TChol (mg/dl) 223 48.33 165.21 29.32
TG (mg/dl) 165.81 94.86 102.42 75.17
HDL-C (mg/dl) 39.47 9.63 44.77 11.29
LDL-C (mg/dl) 150.37 37.85 99.96 20.38
WBC (cells/mL) 7397.6 1717.6 6188.9 1983.
Carotid stenosis (%)b 46.66 7.28 46.89 6.13
Data are mean SD. SBP, systolic blood pressure; DBP, diastolic blood
TG, Triglycerides; HDL-C, high-density lipoprotein-Cholesterol; LDL-C
values of changes of variables between groups.
*p< 0.05 change of variables within groups.
a Comparison within and between groups for HbA1c was performed
b The degree of carotid stenosis contralateral to symptomatic carotAt baseline, no significant differences were detected
between groups (Tables 1 and 2). The anti-hypertensive
medications were modified in 13 patients (group A: eight,
group B: five) to target systolic/diastolic BP <140/
90 mmHg, during the study. The dosage of anti-diabetic
medications was up-titrated in eight patients (group A:
three, group B: five), due to uncontrolled hyperglycaemia
(HbA1c> 7%). The afore-mentioned changes explain the
slight decrease in BP and the significant down-regulation in
HbA1c, within both groups (A: pZ 0.009, B: pZ 0.002).
Effects of Atorvastatin Treatment
As illustrated in Table 2, there was an equivalent improve-
ment in almost all lipid parameters within both groups after
atorvastatin treatment (p< 0.05). There was no significant
difference in changes in lipids between groups. Uponing CAS plus atorvastatin treatment or atorvastatin treatment
Group B (NZ 67) P
Baseline 6 months
29.61 4.74 29.34 4.75 0.295
0.96 0.08 0.95 0.08 0.625
130 19.23 126.06 16.35 0.540
79.06 11.58 77.16 10.95 0.852
6.37 1.08 6.03 1.12* 0.415
126.7 40.4 120.5 38.6 0.123
* 233.36 47.59 170.11 46.13* 0.351
* 156.63 59.64 133.08 57.6* 0.466
* 44.98 10.74 46.96 13.03 0.115
* 157.04 43 96.53 27.95* 0.528
9* 7541.1 2182.6 7096.4 2131.1* 0.260
46.04 7.96 46.31 8.15 0.775
pressure; FPG, fasting plasma glucose; TChol, Total cholesterol;
, low-density lipoprotein-Cholesterol; WBC, white blood cells. P-
only in the diabetic subgroups.
id atherosclerotic lesions.
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decrease from baseline values occurred within groups A
(pZ 0.005) and B (pZ 0.042); however, the treatment
difference between groups was negligible (pZ 0.260). The
degree of the contralateral carotid stenosis remained unal-
tered over time in both groups (p> 0.05).
CAS plus 6-month atorvastatin treatment resulted in
considerable down-regulation in OPN, OPG and hsCRP levels
from baseline (p< 0.001). Similarly, atorvastatin treatment
significantly suppressed OPN (pZ 0.003), OPG (p< 0.001)
and hsCRP (pZ 0.020), levels within group B. The magni-
tude of change in OPN (pZ 0.035), OPG (pZ 0.029) and
hsCRP (pZ 0.045) was significantly greater in group A
versus group B. GSM score of the carotid lesions contralat-
eral to the brain infarct was significantly increased within
both groups (p< 0.01). Notably, the relative increment in
GSM score was more pronounced in group A rather than
group B (pZ 0.041) (Fig. 1).
Correlations
We further assessed the correlations between the changes
of the contralateral GSM score and the changes of the rest
of variables, across the study. We found the GSM score
increment to be inversely associated with the reduction in
OPN (rZ0.286; pZ 0.014), OPG (rZ0.411; pZ 0.011)
and low-density lipoprotein-cholesterol (LDL-C)
(rZ0.234; pZ 0.041). After standard multiple regression
analysis OPN, OPG and LDL-C remained in the model as
independent predictors of GSM improvement (R2Z 0.399;
pZ 0.028).
Discussion
The present 6-month, open-label, prospective study
demonstrated a significant decline in novel cardiovascular
risk factors such as OPN, OPG and hsCRP after combined
treatment with ispilateral CAS plus intensive atorvastatin
therapy in patients with bilateral carotid stenosis. Besides,
after combined treatment, we found that the afore-
mentioned favourable effects were associated with
enhanced contralateral carotid plaque stability.
The current study extended our previous work7 by
reporting statin-induced suppression of serum OPN, OPG and
hsCRP levels in patients with significant carotid stenosis,
which is of clinical importance. Looking for the underlying
mechanisms, previous investigators have suggested the inhi-
bition of mevalonate pathway and protein prenylation to
mediate OPN and OPG suppression.16 Although lipid lowering
contributes to improved cardiovascular outcomes, accumu-
lating evidence supports the lipid-independent cardio-
protective effects of statins over the long term.8 Concerning
the strong relationship of vascular calcification inhibitorswith
cardiovascular diseases and carotid-related symptoma-
tology,3 the atorvastatin-induced suppression ofOPNandOPG
provides an alternative, ‘pleiotropic’ mechanism by which
statins could reduce cardiovascular risk.
Inflammatory and endothelial-related biomolecules
show an acute rise after stenting procedure; most of them
usually return to baseline levels in the long term.17,18 In our
trial, we found the end-study values of OPN, OPG and hsCRPbelow the baseline levels in both groups, but the amount of
their reduction was significantly greater after combined
treatment compared with conservatively treated patients.
Although the latter effects were predominantly attributed
to atorvastatin administration in our statin-naı¨ve patients,
this is the first study demonstrating an adjunctive
improvement of cardiovascular risk profile after combined
treatment with CAS and statin. Atherosclerosis is a diffuse
process, wide-spread on the whole artery tree and each
atherosclerotic lesion constitutes the source of numerous
atherogenic biomolecules entering blood circulation.19,20
Therefore, we postulated statin treatment and athero-
sclerotic plaque compression on the arterial wall, during
CAS, to have restricted cardiovascular biomolecules inva-
sion in circulation. Future studies will investigate the time-
course changes of biomarkers after CAS and the clinical
sequels.
We and other investigators have recently reported the
statin-induced increase in carotid plaque echogenicity.7,21
In the present study, intensive atorvastatin therapy
significantly increased from baseline the GSM score of the
atherosclerotic plaques contralateral to the cerebral
infarct. Most importantly, their echogenicity increased to
a greater extent after combined treatment with ipsilat-
eral CAS plus 6-month intensive atorvastatin treatment
than atorvastatin alone. There is evidence that statins
targeting the systemic risk factors and the triggered
pathways have the potential to attenuate the whole
atherosclerotic progression and plaque vulnerability at
multiple sites of early or advanced atherosclerotic
lesions.22,23 In our study, the inverse relationship
between contralateral GSM score and OPN, OPG and LDL
changes supports the latter hypothesis. Another plausible
explanation for the additional benefits of CAS over 6-
month period derives from the local factors, such as
shear stress, vessel anatomy or haemodynamics, which
are crucial for atherosclerosis progression and may alter
after unilateral carotid revascularisation.24 Endothelial
dysfunction, inflammatory cells infiltration, lipid deposi-
tion, oxidative stress and calcium clustering contribute to
local lesion formation.25 Advanced atherosclerotic pla-
ques act as dynamic sources of inflammatory and calci-
fication mediators entering blood circulation. Plaque-
derived biomolecules further precipitate atherosclerotic
lesions destabilisation.26 Thus, CAS might have attenu-
ated the latter phenomenon via atherosclerotic plaque
destruction and suppression of circulating risk factors,
adding more benefits in intact plaques’ stability. Longer
studies in larger samples will shed more light on the
underlying mechanisms and will confirm the clinical effi-
cacy of CAS plus concomitant statin treatment.
Despite the bilateral symmetry of carotid atheroscle-
rosis, the role of surveillance of the contralateral carotid
artery remains still unclear.27 Previous studies have sug-
gested surveillance of contralateral carotid stenosis to add
little benefit in ischaemic attack prevention.28 Perhaps that
benefit was underestimated since those studies evaluated
lumen narrowing, and were unable to identify vulnerable
plaque composition.29,30 Moreover, bilateral carotid
disease, independent of its severity, is associated with
higher rates of ischaemic events in other arterial territo-
ries, outlining the systemic predisposition to plaque
Figure 1 Serum levels of osteopontin, osteoprotegerin and hsCRP and GSM score values at baseline and at the end of the study.
P1, difference of variables within groups; P2, difference of changes of variables between groups.
CAS Plus Statin Increases Contralateral GSM 263vulnerability.31 In agreement with previous studies, we
strongly suggest that carotid plaque morphology contra-
lateral to the symptomatic carotid stenosis reflects
atherosclerosis progressionas a diffuse disease, and its
monitoring could provide an indication of anti-atherogenic
therapy efficacy.32Our symptomatic patients with significant ipsilateral
carotid stenosis greatly profited from combined treatment
with CAS and statin in terms of cardiovascular risk profile
and contralateral plaque stability. It is still unknown
whether those positive results could be extended to
symptomatic patients with moderate carotid stenosis
264 N.P.E. Kadoglou et al.(<70%). Regarding the degree of carotid stenosis as the
mainstay of patients’ selection, current guidelines under-
line that carotid intervention is probably indicated in
symptomatic patients with stenosis 50e69%.10 Perhaps,
selection criteria other than lumen narrowing classification,
such as cardiovascular biomarkers and imaging features of
plaque texture, could identify ‘vulnerable’ patients, at
high risk for a cardiovascular event, but with haemody-
namically non-significant carotid stenoses who benefit most
from carotid revascularisation. The observed improvement
of cardiovascular risk profile and contralateral carotid
plaque stability outlines the efficacy of combined phar-
maceutical and interventional treatment. Unfortunately,
most trials focus on the comparative evaluation of different
therapeutic strategies of high-risk patients. Our study
supports the multifactorial treatment as the most effective
approach of cardiovascular risk reduction.
The present study has some shortcomings that should be
considered. First, the limited study duration and the modest
sample size did not allow us to draw conclusions on the
differences in the long-term cardiovascular events between
treatment groups. Nevertheless, GSM score constitutes
a valid index of carotid plaque vulnerability, strongly asso-
ciated with cerebrovascular events.1 Perhaps the observed
significant correlations of GSM might have been stronger in
a larger study population. Second, a small proportion of
participants had its concomitantmedicationmodified,which
mighthave influencedour results. Exclusionof thesepatients
from statistical analysis yielded slight changes in the final
outcomes. Furthermore, the interventional group received
dual anti-platelet therapy compared with the single anti-
platelet agent administration to the conservative treatment
group. Regarding the anti-inflammatory properties of anti-
platelet agents, this might have somehow biased the effects
attributed to the stenting procedure and shouldbe taken into
consideration. Finally, our study was confined to hsCRP and
vascular calcification inhibitors. Probably, more systemic
factors could account for our findings.
In conclusion, ispilateral CAS plus intensive atorvastatin
therapy compared with atorvastatin therapy alone was
associated with enhanced carotid plaque stability contra-
lateral to symptomatic carotid stenosis to a greater extent
than atorvastin therapy alone. Amelioration of LDL and
vascular calcification inhibitors levels seemed to mediate
the afore-mentioned favourable effects. Prospective
studies will determine whether the degree of carotid
stenosis is an adequately valid criterion for carotid revas-
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